North Carolina 2017-2018 Session Status: In Committee Bipartisan · 6 R · 3 D cosponsors

SB 175 — Strengthen Opioid Misuse Prevention (STOP)Act.

Last action — Withdrawn From Com

Track this bill free

No card. One bill, free forever — alerts when it moves.

  1. ✓
    Introduced
  2. 2
    In Committee
  3. 3
    Passed Senate
  4. 4
    Passed House
  5. 5
    To Executive
  6. 6
    Enacted

This bill died with 2017-2018 Session. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.

This bill is no longer active — its legislative session has ended, so there is no live prognosis. It would have to be reintroduced in the current session to move again.

Bill Text

What changed in the latest version

452 added · 450 removed

Plain-language change summary

In the updated version of Senate Bill 175, the specific wording about who can prescribe an opioid antagonist, like naloxone, was clarified to ensure that practitioners can prescribe it not just to individuals at risk of overdose, but also to family and friends who might be able to help those individuals. Additionally, the language surrounding the evidence required to justify the prescription has been streamlined. These changes are important because they make it easier for people to obtain life-saving medication and can potentially reduce the number of overdose deaths by ensuring that more individuals have access to naloxone.

→
Previous
Latest
FILED SENATE GENERAL ASSEMBLY OF NORTH CAROLINA Mar 2, 2017 S.B.
GENERAL ASSEMBLY OF NORTH CAROLINA SESSION 2017 S 1 SENATE BILL 175* Short Title:Strengthen Opioid Misuse Prevention (STOP)Act.
175 SESSION 2017 PRINCIPAL CLERK S D SENATE BILL DRS25020-MGfa-35G* (01/26) Short Title:Strengthen Opioid Misuse Prevention (STOP)Act.
Davis, McInnis, and Rabon (Primary Sponsors).
Davis, McInnis, Rabon (Primary Sponsors);
Referred to:
Britt, Brock, Chaudhuri, Clark, Cook, Dunn, B.
A BILL TO BE ENTITLED AN ACT STRENGTHENING OPIOID MISUSE PREVENTION BY EXTENDING STANDING ORDERS FOR OPIOID ANTAGONIST TO COMMUNITY HEALTH GROUPS;
Jackson, Krawiec, Lee, Lowe, Newton, Sanderson, Smith-Ingram, Van Duyn, and Woodard.
Referred toRules and Operations of the Senate March 6, 2017 A BILL TO BE ENTITLED AN ACT STRENGTHENING OPIOID MISUSE PREVENTION BY EXTENDING STANDING ORDERS FOR OPIOID ANTAGONIST TO COMMUNITY HEALTH GROUPS;
(a) As used in this section, "opioid antagonist" means naloxone hydrochloride that is approved by the federal Food and Drug Administration for the treatment of a drug overdose.
*S175-v-1* General Assembly Of North Carolina Session 2017 (a) As used in this section, "opioid antagonist" means naloxone hydrochloride that is approved by the federal Food and Drug Administration for the treatment of a drug overdose.
*DRS25020-MGfa-35G* General Assembly Of North Carolina Session 2017 (b) The following individuals may prescribe an opioid antagonist in the manner prescribed by this subsection:
(b) The following individuals may prescribe an opioid antagonist in the manner prescribed by this subsection:
(e) All of the following individuals are immune from any civil or criminal liability for actions authorized by this section:
Page 2 Senate Bill 175*-First Edition General Assembly Of North Carolina Session 2017 (e) All of the following individuals are immune from any civil or criminal liability for actions authorized by this section:
Page 2 DRS25020-MGfa-35G* [v.1] (01/17) General Assembly Of North Carolina Session 2017 (1) Any practitioner who prescribes an opioid antagonist pursuant to subsection (b) of this section.
(1) Any practitioner who prescribes an opioid antagonist pursuant to subsection (b) of this section.
(3) A practitioner who experiences temporary technological or electrical failure that prevents the prescription from being transmitted electronically;
Senate Bill 175*-First Edition Page 3 General Assembly Of North Carolina Session 2017 (3) A practitioner who experiences temporary technological or electrical failure that prevents the prescription from being transmitted electronically;
provided, DRS25020-MGfa-35G* [v.1] (01/17) Page 3 General Assembly Of North Carolina Session 2017 however, that the practitioner documents the reason for this exception in the patient's medical record.
provided, however, that the practitioner documents the reason for this exception in the patient's medical record.
(i) A manufacturer's sales representative may distribute a controlled substance as a complimentary sample only upon the written request of a practitioner.
Page 4 Senate Bill 175*-First Edition General Assembly Of North Carolina Session 2017 (i) A manufacturer's sales representative may distribute a controlled substance as a complimentary sample only upon the written request of a practitioner.
Such request must be made Page 4 DRS25020-MGfa-35G* [v.1] (01/17) General Assembly Of North Carolina Session 2017 on each distribution and must contain the names and addresses of the supplier and the requester and the name and quantity of the specific controlled substance requested.
Such request must be made on each distribution and must contain the names and addresses of the supplier and the requester and the name and quantity of the specific controlled substance requested.
b.
Senate Bill 175*-First Edition Page 5 General Assembly Of North Carolina Session 2017 b.
DRS25020-MGfa-35G* [v.1] (01/17) Page 5 General Assembly Of North Carolina Session 2017 c.
c.
(e) The Department shall assess, against any pharmacy that employs dispensers found to have failed to report information in the manner required by this section within a reasonable period Page 6 DRS25020-MGfa-35G* [v.1] (01/17) General Assembly Of North Carolina Session 2017 of time after being informed by the Department that the required information is missing or incomplete, a civil penalty of not more than two hundred fifty dollars ($250.00) for a first violation and five hundred dollars ($500.00) for each subsequent violation if the pharmacy fails to report as required under this section, up to a maximum of ten thousand dollars ($10,000) per pharmacy per calendar year.
Page 6 Senate Bill 175*-First Edition General Assembly Of North Carolina Session 2017 (e) The Department shall assess, against any pharmacy that employs dispensers found to have failed to report information in the manner required by this section within a reasonable period of time after being informed by the Department that the required information is missing or incomplete, a civil penalty of not more than two hundred fifty dollars ($250.00) for a first violation and five hundred dollars ($500.00) for each subsequent violation if the pharmacy fails to report as required under this section, up to a maximum of ten thousand dollars ($10,000) per pharmacy per calendar year.
Once the electrical or technological failure has been resolved, the practitioner shall review the information in the controlled substances reporting system pertaining to the patient and the review shall be documented in the patient's medical record.
Once the electrical or technological failure has been resolved, the practitioner shall review the information in the controlled substances Senate Bill 175*-First Edition Page 7 General Assembly Of North Carolina Session 2017 reporting system pertaining to the patient and the review shall be documented in the patient's medical record.
DRS25020-MGfa-35G* [v.1] (01/17) Page 7 General Assembly Of North Carolina Session 2017 (b) A practitioner may, but is not required to, review the information in the controlled substances reporting system pertaining to a patient prior to prescribing a Schedule II through V controlled substance to the patient in any of the following circumstances:
(b) A practitioner may, but is not required to, review the information in the controlled substances reporting system pertaining to a patient prior to prescribing a Schedule II through V controlled substance to the patient in any of the following circumstances:
(a) The Controlled Substances Reporting System Fund is created within the Department as a special revenue fund.
Page 8 Senate Bill 175*-First Edition General Assembly Of North Carolina Session 2017 (a) The Controlled Substances Reporting System Fund is created within the Department as a special revenue fund.
The Department shall use the Page 8 DRS25020-MGfa-35G* [v.1] (01/17) General Assembly Of North Carolina Session 2017 Fund only for operation of the controlled substances reporting system and to carry out the provisions of this Article.
The Department shall use the Fund only for operation of the controlled substances reporting system and to carry out the provisions of this Article.
(8) Any other data deemed appropriate and requested by the Joint Legislative Oversight Committee on Health and Human Services, the North Carolina DRS25020-MGfa-35G* [v.1] (01/17) Page 9 General Assembly Of North Carolina Session 2017 Medical Board, the North Carolina Board of Nursing, the North Carolina Dental Board, the North Carolina Veterinary Medical Board, or the North Carolina Board of Pharmacy." 5 PART VI.
Senate Bill 175*-First Edition Page 9 General Assembly Of North Carolina Session 2017 (8) Any other data deemed appropriate and requested by the Joint Legislative Oversight Committee on Health and Human Services, the North Carolina Medical Board, the North Carolina Board of Nursing, the North Carolina Dental Board, the North Carolina Veterinary Medical Board, or the North Carolina Board of Pharmacy." 7 PART VI.
Page 10 DRS25020-MGfa-35G* [v.1] (01/17)
Page 10 Senate Bill 175*-First Edition
⬇ Download PDF
View plain text versions (2)

Action History

  1. Withdrawn From Com

  2. Re-ref to Health Care. If fav, re-ref to Judiciary. If fav, re-ref to Appropriations/Base Budget. If fav, re-ref to Rules and Operations of the Senate

  3. Passed 1st Reading

  4. Ref To Com On Rules and Operations of the Senate

  5. Filed

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

2 sponsors · 16 co-sponsors · 161 not signed on

Sponsors (2)

Co-sponsors (16)

Not signed on (161)

161 members have not signed on to this bill.

Show all 161 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

public-safety healthcare health-insurance
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

Who sponsors SB 175?
SB 175 is sponsored by Woodard, Van Duyn, Norman W. Sanderson (Republican), Bill Rabon (Republican), Tom McInnis (Republican), Paul A. Lowe, Jr. (Democratic), Krawiec, Dunn, Cook, Clark, Jay J. Chaudhuri (Democratic), Brock, Danny Earl Britt, Jr. (Republican), Newton, D. Davis, Brent Jackson (Republican), Michael V. Lee (Republican), and Kandie D. Smith (Democratic).
What is the current status of SB 175?
This bill died with 2017-2018 Session. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
Where can I track SB 175?
Track SB 175 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on SB 175

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of SB 175

Last checked for changes 3 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →